uu.seUppsala University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Synthesis and comperative molecular field analysis (CoMFA) of symmetric and nonsymmetric cyclic sulfamide HIV-1 protease inhibitors
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Pharmacy, Department of Medicinal Chemistry. (Organic Pharmaceutical Chemistry)ORCID iD: 0000-0001-6770-0878
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Pharmacy, Department of Medicinal Chemistry. (Organic Pharmaceutical Chemistry)
Uppsala University, Disciplinary Domain of Science and Technology, Chemistry, Department of Biochemistry.
Uppsala University, Disciplinary Domain of Science and Technology, Biology, Department of Cell and Molecular Biology.
Show others and affiliations
2001 (English)In: Journal of Medicinal Chemistry, ISSN 0022-2623, E-ISSN 1520-4804, Vol. 44, no 2, p. 155-169Article in journal (Refereed) Published
Place, publisher, year, edition, pages
2001. Vol. 44, no 2, p. 155-169
National Category
Pharmaceutical Sciences Biological Sciences
Identifiers
URN: urn:nbn:se:uu:diva-93068DOI: 10.1021/jm001024jOAI: oai:DiVA.org:uu-93068DiVA, id: diva2:166434
Available from: 2005-05-12 Created: 2005-05-12 Last updated: 2018-03-05Bibliographically approved
In thesis
1. Cyclic Sulfamide HIV-1 Protease Inhibitors: Design, Synthesis and Modelling
Open this publication in new window or tab >>Cyclic Sulfamide HIV-1 Protease Inhibitors: Design, Synthesis and Modelling
2005 (English)Doctoral thesis, comprehensive summary (Other academic)
Abstract [en]

Ten years ago, the first protease inhibitor targeting the human immunodeficiency virus (HIV) was approved for clinical use. Highly active antiretroviral therapy (HAART), which combined protease and reverse transcriptase inhibitors, quickly became the standard therapy for treating patients infected with HIV and Acquired Immune Deficiency Syndrome (AIDS). Nevertheless, last year the AIDS pandemic reached its highest level ever. Many infected patients, mainly in the developing countries, are still without treatment. Among those patients who receive treatment, an increase in drug resistance and new-infection with drug-resistant strains are seen. To come to terms with these problems, new drugs that are efficient against resistant strains and can be produced at low cost are needed.

In this study, we have focused our research efforts on cyclic sulfamides active as HIV-1 protease inhibitors. Distinctive to this compound class, as compared to the inhibitors so far approved for clinical use, was the incorporation of a water mimic that displaces the structural water (W301) observed in the X-ray crystal co-complexes. The first part of the study was aimed at understanding the rationale behind the nonsymmetric binding mode that the inhibitor adopted when bound to the enzyme. Symmetric and nonsymmetric inhibitors were synthesized and the structure-activity relationships and preferable binding modes were rationalized with the help of Comparative Molecular Field Analysis (CoMFA).

In the second part of the study, an attempt was made to reduce the size of these inhibitors. As a result, the traditional P1/P1' substituents were removed, while the P2/P2' substituents were elongated in an attempt to reach between the binding sites. The design hypothesis was shown to be successful and inhibitors possessing nanomolar activity were identified.

Place, publisher, year, edition, pages
Uppsala: Acta Universitatis Upsaliensis, 2005. p. 75
Series
Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Pharmacy, ISSN 1651-6192 ; 11
Keywords
Pharmaceutical chemistry, AIDS, HIV, protease inhibitor, aspartic protease, molecular modelling, 3D-QSAR, CoMFA, Farmaceutisk kemi
National Category
Medicinal Chemistry
Identifiers
urn:nbn:se:uu:diva-5803 (URN)91-554-6253-7 (ISBN)
Public defence
2005-06-03, B41, BMC, Husargatan 3, Uppsala, 10:15
Opponent
Supervisors
Available from: 2005-05-12 Created: 2005-05-12 Last updated: 2018-01-13Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full text

Authority records BETA

Schaal, WesleyDanielson, U. Helena

Search in DiVA

By author/editor
Schaal, WesleyDanielson, U. Helena
By organisation
Department of Medicinal ChemistryDepartment of BiochemistryDepartment of Cell and Molecular Biology
In the same journal
Journal of Medicinal Chemistry
Pharmaceutical SciencesBiological Sciences

Search outside of DiVA

GoogleGoogle Scholar

doi
urn-nbn

Altmetric score

doi
urn-nbn
Total: 904 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf